Advertisement
NVO vs NVS
Which Stock Would AI Choose? Novo Nordisk (NVO) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- NVO is a high-growth but higher-risk play concentrated in diabetes and obesity (GLP-1) treatments, while NVS is a diversified innovative-medicines company spanning oncology, immunology, neuroscience, and cardiovascular-renal-metabolic care.
- Novo Nordisk remains in a technical downtrend amid pricing pressure and intensifying competition, whereas Novartis shows a more stable trend and stronger relative market positioning.
- Tickeron AI Verdict: Based on trend consistency, stability, and relative positioning, Tickeron's AI currently favors NVS over NVO.
- For more detail, explore NVO Major News and NVO Today's Price Move, as well as NVS Major News and NVS Today's Price Move.
- Discover how AI-driven strategies navigate this matchup by exploring Trending AI Robots.
Introduction
Novo Nordisk (NVO) and Novartis (NVS) are two of Europe's largest pharmaceutical companies, yet they sit at very different points in their market cycles. Novo Nordisk is a Denmark-based leader in diabetes and obesity care whose fortunes have been reshaped by the global GLP-1 (glucagon-like peptide-1) boom — and by rising competition. Novartis is a Swiss "pure-play" innovative-medicines firm with a diversified pipeline across four therapeutic areas. This stock comparison is relevant for investors weighing a high-growth but volatile obesity franchise against a broader, cash-generative diversified drugmaker, and for traders assessing relative performance and market positioning in the current environment.
NVO Overview and Recent Performance
Novo Nordisk is a global healthcare company focused on diabetes, obesity, and other serious chronic diseases. Its core franchise centers on semaglutide-based GLP-1 therapies — Wegovy for weight loss and Ozempic for diabetes — alongside a growing portfolio of next-generation treatments. After a historic rise that peaked in mid-2024, NVO has experienced a sharp multi-year decline, with its market value down roughly 70% from its all-time high. Recent market activity has reflected ongoing pricing pressure in the U.S., guidance for declining adjusted sales and operating profit, and a failed late-stage cardiovascular trial. In recent weeks, however, sentiment has been lifted by new CagriSema weight-loss data showing average losses of roughly 25% in adult women, by strong uptake of oral Wegovy, and by regulatory progress for high-dose Wegovy. These catalysts have generated optimism about the pipeline, even as technical signals remain weak.
NVS Overview and Recent Performance
Novartis is a Switzerland-based innovative-medicines company concentrated in cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. Its portfolio includes blockbuster brands such as Kisqali, Kesimpta, Pluvicto, Scemblix, Cosentyx, and Leqvio. For full-year 2025, NVS reported net sales up 8% to roughly $54.5 billion and core operating income up 14% at constant currencies, reaching a core operating margin of 40.1%. Free cash flow of about $17.6 billion underpinned a proposed dividend increase. Recent weeks have been shaped by Novartis entering what management calls the largest patent expiry in its history, as generic competition pressures legacy products such as Entresto. Still, the company's growth brands have sustained double-digit momentum, and its technical trend has remained relatively constructive compared with peers, supporting a steadier relative performance profile.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and set of covered securities. Because no single approach fits every market condition, only the bots best suited to the current environment earn a place in the curated Trending AI Robots section. This shortlist highlights the strategies demonstrating the most relevant and timely positioning right now, giving investors a focused way to explore AI-driven signals across names like NVO and NVS. Browsing the page can help you evaluate how automated systems are interpreting current momentum and volatility.
Head-to-Head Comparison
The two companies offer contrasting risk-and-reward profiles. NVO is essentially a concentrated bet on the obesity and diabetes market, where its growth drivers — oral and high-dose Wegovy, CagriSema, and earlier-stage assets — carry substantial upside but also binary clinical and competitive risk. Its key threats include pricing erosion, generic competition as patents approach expiry, and Eli Lilly's dominance in weight loss. NVS, by contrast, spreads exposure across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease, providing diversification that has historically supported more consistent cash flow and shareholder returns. Its primary headwind is the 2026 patent cliff, though a deep pipeline and new technology platforms are intended to offset that erosion. On momentum, NVS has displayed a steadier technical trend, while NVO remains in a recovery phase with a weaker chart profile.
Tickeron AI Verdict
Weighing trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor NVS over NVO in the current environment. Novartis's diversified revenue base, strong cash generation, and comparatively constructive technical trend present a more stable setup, even with the patent cliff in view. Novo Nordisk's obesity franchise offers meaningful long-term optionality, but its ongoing pricing headwinds and weaker trend structure introduce greater uncertainty. The verdict reflects a probabilistic assessment of current market conditions rather than a definitive claim about either company's long-term prospects.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVO is a Hold and NVS is a Hold.
NVO's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NVO turned positive on October 08, 2026. Looking at past instances where NVO's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on NVO as a result. In 54 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in 203 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 163 of 255 cases where NVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 24 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 72 cases where NVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
NVO moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
NVO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.805) is normal, around the industry mean (-1.360). P/E Ratio (1.534) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (4.416) is also within normal values, averaging (5.738). Dividend Yield (0.046) settles around the average of (0.038) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
NVS in upward trend: 10-day moving average broke above 50-day moving average on October 22, 2026
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 43 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 187 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.360). P/E Ratio (24.370) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).
NVO | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 4 | |
SMR RATING 1..100 | 19 | 33 | |
PRICE GROWTH RATING 1..100 | 58 | 40 | |
P/E GROWTH RATING 1..100 | 97 | 13 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (54) in the Pharmaceuticals Major industry is in the same range as NVO (65). This means that NVS’s stock grew similarly to NVO’s over the last 12 months.
NVS's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is significantly better than the same rating for NVO (100). This means that NVS’s stock grew significantly faster than NVO’s over the last 12 months.
NVO's SMR Rating (19) in the Pharmaceuticals Major industry is in the same range as NVS (33). This means that NVO’s stock grew similarly to NVS’s over the last 12 months.
NVS's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as NVO (58). This means that NVS’s stock grew similarly to NVO’s over the last 12 months.
NVS's P/E Growth Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for NVO (97). This means that NVS’s stock grew significantly faster than NVO’s over the last 12 months.
| NVO | NVS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 67% | 2 days ago 54% |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 38% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 54% |
| MACD ODDS (%) | 2 days ago 79% | N/A |
| TrendWeek ODDS (%) | 2 days ago 65% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 66% | 2 days ago 51% |
| Advances ODDS (%) | 6 days ago 65% | 12 days ago 55% |
| Declines ODDS (%) | 11 days ago 67% | N/A |
| BollingerBands ODDS (%) | 2 days ago 57% | 2 days ago 30% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVO’s FA Score shows that 1 FA rating(s) are green while NVS’s FA Score has 3 green FA rating(s).
- NVO’s FA Score: 1 green, 4 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVO’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
- NVO’s TA Score: 4 bullish, 5 bearish.
- NVS’s TA Score: 5 bullish, 4 bearish.
Price Growth
NVO (@Pharmaceuticals: Major) experienced а +0.78% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
Reported Earning Dates
NVO is expected to report earnings on Feb 03, 2027.
NVS is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
NVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVO has been loosely correlated with TECH. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if NVO jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To NVO | 1D Price Change % | ||
|---|---|---|---|---|
| NVO | 100% | +0.02% | ||
| TECH - NVO | 36% Loosely correlated | +0.17% | ||
| GMAB - NVO | 35% Loosely correlated | +1.69% | ||
| NVS - NVO | 29% Poorly correlated | +0.38% | ||
| AXON - NVO | 29% Poorly correlated | -18.18% | ||
| IMTX - NVO | 29% Poorly correlated | +2.91% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.